Independent pharmaceutical company Ethypharm has signed an agreement to acquire the UK-based specialty pharmaceutical company, Martindale Pharma, which specialises in the field of opioid addiction, emergency care and sterile injectables.
pharma
The deal will reinforce Ethypharm’s position in the UK and help broaden its geographical reach. Ethypharm’s manufacturing capabilities in solid dose, injectables and oral liquids will also benefit from the agreement.
The combination of the two companies will create a group with revenues of more than €300 million and a solid platform for future growth.
Michael Harris, CEO of Martindale Pharma and future chief operating officer of Ethypharm, said: “The combination of Ethypharm and Martindale enables us to create a leading company in the fields of emergency care, pain and addiction. It allows us to take our products into many other markets helping patients around the world get access to better medicines.”
Hugues Lecat, CEO of Ethypharm, said: “I am delighted to welcome the Martindale Pharma team within Ethypharm. The combined group will benefit from Martindale’s expertise and talents to accelerate its international growth.”